

WEST**End of Result Set**☐ **Generate Collection**

L8: Entry 19 of 19

File: DWPI

Dec 21, 1995

DERWENT-ACC-NO: 1996-040798

DERWENT-WEEK: 199605

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Pharmaceutical compsn. for inhalation - contains dosage dependent antiinflammatory and bronchodilator, esp. xanthine or phosphodiesterase inhibitor

PATENT-ASSIGNEE:

ASSIGNEE

EUROCELTIQUE SA

CODE

EURON

PRIORITY-DATA: 1994DE-4420708 (June 14, 1994)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

DE 4420708 A1

December 21, 1995

004

A61K009/12

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

DE 4420708A1

June 14, 1994

1994DE-4420708

INT-CL (IPC): A61K 9/12; A61K 31/52

ABSTRACTED-PUB-NO: DE 4420708A

BASIC-ABSTRACT:

Pharmaceutical compsn. formulated for admin. by inhalation contains an active agent which has antiinflammatory activity as well as bronchodilatory activity at a dosage higher than that required to produce the antiinflammatory effect, pref. a xanthine or phosphodiesterase inhibitor. The active agent is pref. theophylline (1,3-dimethylxanthine).

USE - The compsn. is used to treat inflammatory conditions of the bronchi and esp. the lungs.

ADVANTAGE - The compsn. does not have the problems associated with the admin. of effective unit doses of bronchodilators by inhalation. Further, it is more effective than oral formulations.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: PHARMACEUTICAL COMPOSITION INHALE CONTAIN DOSE DEPEND
ANTIINFLAMMATORY BRONCHODILATING XANTHINE PHOSPHODIESTERASE INHIBIT

DERWENT-CLASS: B02

CPI-CODES: B04-A06; B04-M01; B12-M01B; B14-C03; B14-D03; B14-K01D;

CHEMICAL-CODES:

Chemical Indexing M2 *01*
Fragmentation Code

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	"phosphodiesterase inhibitor" and propellant and inhalation	11	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI	"phosphodiesterase inhibitor" and xanthine and inhalation	19	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI	aqueous and cGMP and PDE and (particulate or powder) and (inhalation or inhalable or atomisable or nebulizable or nebulization) and propellant	32	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI	aqueous and cGMP and PDE and (particulate or powder) and (inhalation or inhalable or atomisable or nebulizable or nebulization)	96	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI	aqueous and cGMP and PDE and (particulate or powder or finely) and (inhalation or inhalable or atomisable or nebulizable or nebulization)	100	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI	aqueous and cGMP and PDE and (inhalation or inhalable or atomisable or nebulizable or nebulization)	127	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI	"erectile dysfunction" and cGMP and PDE and (inhalation or inhalable or atomisable or nebulizable or nebulization)	16	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI	"sexual dysfunction" and cGMP and PDE and (inhalation or inhalable or atomisable or nebulizable or nebulization)	9	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	"sexual dysfunction" and cGMP and PDE and aerosol	5	<u>L1</u>